HDAC9 and lung carcinoma: EGFR-TKIs (e.g., gefitinib, osimertinib) combined with pan-HDAC inhibitors (e.g., trichostatin A, vorinostat) enhance growth inhibition and synergistically reduce the viability of EGFR-mutant lung cancer cells through apoptosis [2,5].